Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company acquired pemvidutide through the acquisition of Spitfire Pharma Inc. in July 2019. Pemvidutide has received Breakthrough Therapy Designation and Fast Track designation from the FDA for MASH. The company is currently evaluating pemvidutide in ongoing clinical trials for AUD and ALD, with evidence suggesting it may decrease alcohol cravings and reverse harmful liver effects. The drug is protected by a patent portfolio with expiration dates extending into the 2040s.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage altimmune.com
Sector Healthcare IR page ir.altimmune.com
Tags
liver diseases, mash, alcohol use disorder, alcohol-associated liver disease, glucagon receptor agonist, glp-1 receptor agonist, dual receptor agonist, peptide therapeutics, metabolic dysfunction, hepatic fibrosis, pemvidutide, ALT-801, Spitfire Pharma Inc., IMPACT, MOMENTUM
Press page —

Metrics

Valuation  
Market cap $ 275.991M
Market cap (USD) $ 275.991M
P/E -2.00
PEG —
P/BV 0.62
P/S —
P/OCF -2.70
P/FCF -4.09
Dividend yield —
Turnover / mcap —
Returns  
ROE -50.6%
ROI -34.0%
ROIC -27.3%
Profit margin -214,861.0%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity 7.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 46
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 41K 20K 426K -68K 4.41M 8.185M 5.801M 10.331M 10.738M — — — — — 24.266M 20.994M — — 14.625M —
Net profit -88.093M -95.059M -88.447M -84.713M -97.091M -49.044M -20.52M -39.171M -46.425M 193.854M -3.441M -9.955M -11.718M -4.92M -3.798M -34.849M -32.28M -36.415M -13.587M —
Free cash flow -67.546M -79.848M -75.857M -62.712M -90.355M -34.641M -9.603M -10.364M -20.327M 201.478M -3.302M -8.566M -7.253M — -7.88M -15.239M -29.175M -13.708M -14.519M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 3.61 7.21 11.25 16.45 9.16 11.28 1.89 2.06 1.99 — — — — — — — — — — 0.15
Price performance 12m -0.5 -0.36 -0.32 0.8 -0.19 4.97 -0.08 0.04 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — — 1.85M 1.86M 1.83M 1.45M 4.58M — — 34.3M
Lease liabilities (USD) — — — 1.74M 1.82M 1.54M 1.12M 671,000 1.68M 1.4M
Cash and deposits (USD) 154M 8.77M 33.7M 8.96M 116M 190M 111M 135M 36.9M 43.8M
Intangible assets (USD) 15M 38.7M 13.9M 12.7M 12.8M 12.4M 12.4M 0.00 0.00 —
Right-of-use assets (USD) — — — 698,321 903,825 798,178 596,000 363,000 1.64M 1.43M
Net debt (borrowings + leases - cash) (USD) — — -31.9M -5.35M -112M -187M -105M — — -8.07M
Cash flow detail
Operating cash flow (USD) 202M -20.2M -9.39M -9.6M -34.4M -78.2M -62.6M -75.8M -79.8M -67.5M
Purchases of property, plant and equipment (USD) -30,687 -112,441 -975,407 -1,227 -203,957 -12.1M -126,000 -47,000 — -11,000
Purchases of intangible assets (USD) -95,615 -53,886 -40,227 -27,772 -138,464 -194,538 — — — —
Change in receivables (cash effect) (USD) 210,170 -1.95M 344,301 2.44M -3.59M 4.18M 256,000 -938,000 567,000 -675,000
Change in payables (cash effect) (USD) 405,407 -2.62M 243,062 -354,628 594,060 1.42M 2.77M -2.73M -1.86M 2.51M
Interest paid (cash effect) (USD) 0.00 -9,352 -57,214 — -1,791 — — — — -975,000
Share-based compensation (USD) 2.24M 1.44M 773,248 1.26M 2.58M 5.52M 8.1M 10.6M 14.4M 16.1M
Operating cash flow before change in receivables (USD) 201M -18.3M -9.73M -12M -30.8M -82.4M -62.8M -74.9M -80.4M -66.9M
Free cash flow (OCF - PPE - intangibles) (USD) 201M -20.4M -10.4M -9.63M -34.8M -90.5M -62.7M -75.9M — -67.5M
Income detail
Research and development expense (USD) 4.84M 18.4M 18.5M 17.8M 49.8M 74.5M 70.5M 65.8M 82.2M 66.4M
↳ 5y CAGR -25.6% -1.2% +3.8% +13.8% +57.5% +72.8% +30.8% +28.9% +35.9% +5.9%
Total comprehensive income (USD) 194M -43.4M -39.6M -20.5M -49.1M -97.1M -84.9M -88.2M -95M -88M
Comprehensive income to owners (USD) 194M -43.4M -39.6M — — — — — — —
Reported Apr 2, 2018 Apr 2, 2018 May 14, 2019 Mar 27, 2020 Mar 15, 2022 Mar 15, 2022 Feb 28, 2023 Mar 27, 2024 Feb 27, 2025 Mar 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation

at AASLD The Liver Meeting® 2026

End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026

$480 million in cash, cash equivalents and investments as of September 30, 2026

Webcast to be held today at 8:30 a.m. ET

MORRISTOWN, NJ – November 12, 2026 – Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide” said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. “Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community.

November 5, 2026 at 8:00 AM EST

Download PDF

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that it will report its third quarter 2026 financial results on Thursday, November 12, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on November 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website.

Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About AltimmuneAltimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. onLinkedIn Follow @AltimmuneInc onX

Investor Contact: Luis Sanay, CFA [email protected]

Media Contact: Marisa Sharkey [email protected]

Primary Logo

Investor Contact

Email: [email protected]

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe

altimmune logo

350 Mount Kemble Avenue Suite 1001 Morristown, NJ 07960 (862) 457-1450

Nav ALTIMMUNE

Altimmune

Nav Pipeline

Pipeline

Nav IR

Investors

© 2026 Altimmune. All rights reserved.

Social

Nav About Us

Nav Pipeline

Nav IR

Nav Clinical Trials

Nav Partnerships

Nav Contact

November 5, 2026 at 10:00 AM EST

Download PDF

First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)

Presentation to take place on Monday, November 9, 2026, at The Liver Meeting

Company scheduled to hold End-of-Phase 2 meeting with FDA in December

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted as an oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

This first presentation at an international scientific conference will feature key results from RECLAIM, a randomized, double-blind, placebo-controlled trial evaluating once-weekly pemvidutide 2.4 mg versus placebo over 24 weeks. In topline results announced in July 2026, pemvidutide achieved the trial’s primary endpoint of a statistically significant reduction in heavy drinking days (HDD) per week compared with placebo, and met key secondary endpoints validated by the U.S. Food and Drug Administration (FDA) as registrational endpoints, including reduction in World Health Organization (WHO) Risk Drinking Levels and zero HDD, with a generally favorable tolerability profile.

Late-breaking abstracts at The Liver Meeting are reserved for new, scientifically important findings from prospective large clinical studies or high-impact translational research that could not be completed before the regular abstract deadline.

Details of the late-breaking oral presentation are as follows:

  • Abstract Title: Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial

  • Session: Late-Breaker Session 3

  • Date/Time: Monday, November 9, 2026, 10:30 a.m. MT / 12:30 p.m. ET

  • Presenter: Henry R. Kranzler, M.D. Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine

A copy of this presentation will be accessible on the Events section of the Altimmune website immediately following the late-breaker session.

Additionally, the Company is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for pemvidutide in AUD.

About RECLAIM

RECLAIM (NCT06987513) is a Phase 2 trial evaluating the safety and efficacy of pemvidutide in Alcohol Use Disorder (AUD) patients with BMI >25 kg/m2, and is the first Phase 2 multicenter study evaluating a dual glucagon-GLP-1 agonist in AUD to report results. Approximately 100 patients were randomized 1:1 to receive either 2.4 mg pemvidutide or placebo once weekly for 24 weeks. The primary endpoint of the trial was the change from baseline in the average number of heavy drinking days (HDD) per week, with secondary endpoints including the proportion of patients achieving a 2-level reduction in World Health Organization (WHO) Risk Drinking Levels (RDL), zero HDD, and absolute change from baseline in average levels of phosphatidylethanol (PEth), an objective serum biomarker of alcohol intake. The 2-level reduction in WHO risk drinking levels and zero HDD are recognized by the FDA as registrational endpoints.

About Pemvidutide

Pemvidutide is a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial in ALD.

About Altimmune Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Investor Contact: Luis Sanay, CFA [email protected]

Media Contact: Marisa Sharkey [email protected]

Primary Logo

Investor Contact

Email: [email protected]

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe

altimmune logo

350 Mount Kemble Avenue Suite 1001 Morristown, NJ 07960 (862) 457-1450

Nav ALTIMMUNE

Altimmune

Nav Pipeline

Pipeline

Nav IR

Investors

© 2026 Altimmune. All rights reserved.

Social

Nav About Us

Nav Pipeline

Nav IR

Nav Clinical Trials

Nav Partnerships

Nav Contact

Prompts

Altimmune, Inc. (ticker ALT), listed in United States.

Company History

Date Change Detail
Mar 2, 2017 Renamed PHARMATHENE, INC → ALTIMMUNE, INC.
Oct 29, 2007 Renamed HEALTHCARE ACQUISITION CORP → PHARMATHENE, INC

ETFs Holding Altimmune, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.07% 1,260 $ 3,830.40 Jun 30, 2026
FESM 0.03% 638,025 $ 1.94M Jun 30, 2026
RESM 0.02% 214 $ 650.56 Jun 30, 2026
AVSC 0.01% 107,722 $ 168.046K Nov 16, 2026
DFAS 0.00% 167,692 $ 269.984K Nov 12, 2026
DFAC 0.00% 34,439 $ 55.447K Nov 12, 2026
DCOR 0.00% 8,167 $ 13.149K Nov 12, 2026
AVSU 0.00% 763 $ 1,190.28 Nov 16, 2026